DPP-4 inhibitors are recommended for use in individuals with T2D and CVD due to their neutral cardiovascular profile, offering effective glycemic control without increasing the risk of major adverse cardiovascular events. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.